Cargando…
FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer
Neoadjuvant chemotherapy is the preferred treatment of advanced gastric cancer. However, the choice of an optimal regimen remains controversial. The present study aimed to assess the effectiveness of preoperative chemotherapy with EOX and FOLFOX in Chinese patients with advanced gastric cancer. A to...
Autores principales: | CHEN, WENJUN, SHEN, JIANGUO, PAN, TAO, HU, WENXIAN, JIANG, ZINONG, YUAN, XIAOMING, WANG, LINBO |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3881068/ https://www.ncbi.nlm.nih.gov/pubmed/24396426 http://dx.doi.org/10.3892/etm.2013.1449 |
Ejemplares similares
-
Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX)
por: Wang, Yan, et al.
Publicado: (2016) -
A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for
locally advanced gastric cancer
por: Wang, Xiang, et al.
Publicado: (2016) -
A Case of Complete Remission from Advanced Gastric Adenocarcinoma with Synchronous Liver Metastasis in Response to EOX Chemotherapy
por: Yan, Zhi-jun, et al.
Publicado: (2018) -
A Modified Epirubicin and Oxaliplatin Plus Capecitabine (EOX) Regimen as a Second- Line Therapy in Patients with Advanced Gastric Cancer
por: Bozkaya, Yakup, et al.
Publicado: (2018) -
XELOX doublet regimen versus EOX triplet regimen as first‐line treatment for advanced gastric cancer: An open‐labeled, multicenter, randomized, prospective phase III trial (EXELOX)
por: Zhu, Xiao‐Dong, et al.
Publicado: (2022)